Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat. CEO Marcio Souza will participate in a discussion with TD Cowen's Biotechnology Analyst Ritu Baral on September 2, 2025, at 10:00 AM EST.
The discussion will focus on Praxis' recent presentations at the 36th International Epilepsy Consortium (IEC). The company specializes in developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines (NASDAQ: PRAX), una societ脿 biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per i disturbi del sistema nervoso centrale, ha annunciato un prossimo incontro virtuale in stile "fireside chat". L'amministratore delegato Marcio Souza parteciper脿 a una discussione con Ritu Baral, analista di biotecnologie di TD Cowen il 2 settembre 2025 alle 10:00 EST.
Il confronto verter脿 sulle recenti presentazioni di Praxis al 36掳 International Epilepsy Consortium (IEC). L'azienda 猫 specializzata nello sviluppo di trattamenti per disturbi del sistema nervoso centrale caratterizzati da uno squilibrio tra eccitazione e inibizione neuronale.
Praxis Precision Medicines (NASDAQ: PRAX), una compa帽铆a biofarmac茅utica en fase cl铆nica centrada en el desarrollo de terapias para trastornos del sistema nervioso central, ha anunciado una pr贸xima charla virtual tipo "fireside chat". El director ejecutivo Marcio Souza participar谩 en una conversaci贸n con Ritu Baral, analista de biotecnolog铆a de TD Cowen el 2 de septiembre de 2025 a las 10:00 AM EST.
La discusi贸n se centrar谩 en las presentaciones recientes de Praxis en el 36.潞 International Epilepsy Consortium (IEC). La compa帽铆a se especializa en desarrollar tratamientos para trastornos del sistema nervioso central caracterizados por un desequilibrio entre excitaci贸n e inhibici贸n neuronal.
Praxis Precision Medicines (NASDAQ: PRAX)電� 欷戩稊鞁犼步瓿�(CNS) 鞛レ暊 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎届偓搿�, 瓿� 臧赌靸� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞚� 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 斓滉碃瓴届榿鞛� Marcio Souza臧赌 TD Cowen鞚� 靸濍獏瓿淀暀 鞎犽剱毽姢韸� Ritu Baral瓿� 2025雲� 9鞗� 2鞚� 鞓れ爠 10:00(霃欕秬 響滌鞁�)鞐� 雽�雼挫棎 彀胳棳頃╇媹雼�.
鞚措矆 雽�雼挫潃 鞝�36須� International Epilepsy Consortium(IEC)鞐愳劀鞚� Praxis 斓滉芳 氚滍憸毳� 欷戩嫭鞙茧 歆勴枆霅╇媹雼�. 鞚� 須岇偓電� 頋ル秳瓿� 鞏奠牅鞚� 攵堦窢順曥溂搿� 韸轨歆�鞏挫電� 鞁犼步瓿� 鞛レ暊 旃橂 臧滊皽鞚� 鞝勲鞙茧 頃╇媹雼�.
Praxis Precision Medicines (NASDAQ: PRAX), une soci茅t茅 biopharmaceutique en phase clinique d茅di茅e au d茅veloppement de th茅rapies pour les troubles du syst猫me nerveux central, a annonc茅 une prochaine discussion virtuelle de type "fireside chat". Le directeur g茅n茅ral Marcio Souza participera 脿 un 茅change avec Ritu Baral, analyste en biotechnologie chez TD Cowen le 2 septembre 2025 脿 10h00 EST.
La discussion portera sur les r茅centes pr茅sentations de Praxis au 36e International Epilepsy Consortium (IEC). L'entreprise est sp茅cialis茅e dans le d茅veloppement de traitements pour les troubles du syst猫me nerveux central caract茅ris茅s par un d茅s茅quilibre entre excitation et inhibition neuronales.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in klinischer Phase mit Schwerpunkt auf der Entwicklung von Therapien f眉r Erkrankungen des zentralen Nervensystems, hat ein bevorstehendes virtuelles "Fireside Chat" angek眉ndigt. CEO Marcio Souza wird am 2. September 2025 um 10:00 Uhr EST an einem Gespr盲ch mit Ritu Baral, Biotechnologie-Analystin bei TD Cowen, teilnehmen.
Die Diskussion wird sich auf Praxiss j眉ngste Pr盲sentationen beim 36. International Epilepsy Consortium (IEC) konzentrieren. Das Unternehmen spezialisiert sich auf die Entwicklung von Behandlungen f眉r Erkrankungen des zentralen Nervensystems, die durch ein Ungleichgewicht von neuronaler Erregung und Hemmung gekennzeichnet sind.
- None.
- None.
BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36th International Epilepsy Consortium (IEC).
The registration link for the fireside chat can be found .
The overview of Praxis鈥� posters and presentation at the IEC event can be found .
About Praxis鈥�
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽聽and follow us on聽,听,听听补苍诲听.
Investor Contact:聽 Praxis Precision Medicines聽 [email protected]聽 857-702-9452聽 聽 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
When is Praxis Precision Medicines (PRAX) fireside chat scheduled for September 2025?
What will be discussed during the PRAX fireside chat with TD Cowen?
Who is hosting the September 2025 fireside chat for Praxis Precision Medicines?
What type of therapies is Praxis Precision Medicines (PRAX) developing?
